| Objectives:To study whether vitamin K2 supplementation affects their coagulation function in healthy individuals who have not received anticoagulant therapy.Method:Forty healthy men and women aged 25 to 40 were recruited and received 90ug of vitamin K2(MK-7)daily.On days 0,7,and 30 after vitamin K2 supplementation,peripheral blood was collected to measure blood coagulation indicators:activated partial thromboplastin time(APTT),fibrinogen(FIB),prothrombin time(PT),thrombin time(TT),international normalised ratio(INR),factor ? activity(F?:C),factor ? activity(F?:C),factor F? activity(F?:C)and factor ? activity(FX:C).In addition,the plasma was diluted 1:5 and 1:10 to measure the vitamin K-dependent coagulation factors activities(F?:C?F?:C?F?:C?F?:C)at 0 and 30 days.On days 0 and 30 after vitamin K2 supplementation,peripheral blood was collected to measure abnormal prothrombin(PIVKA-?)and dephospho-uncarboxylated matrix Gla protein(dp-ucMGP)levels.Result:1.APTT of the the baseline,7 days and 30 days were 33.51±.35s,33.63±2.14s and 33.53±2.09s respectively;FIB were 262.23 ±20.21mg/dL,261.28±18.75mg/dL and 262.80±19.04mg/dL respectively;INR were 1.13±0.08,1.11±0.07 and 1.12±0.07 respectively,PT were 11.83 ± 0.61s,11.86 ± 0.57s and 11.97 ± 0.56s respectively,TT were 15.08 ±1.17s,14.81±0.94s and 14.83±1.08s respectively,and the difference of all parameters among the three periods were not statistically significant(P>0.05 for all parameters).2.F?:C of the the baseline,7 days and 30 days were 99.96±10.24%,99.97±8.96%and 97.28±12.42%respectively;F?:C were 76.40±12.33%,77.72±13.04%and 76.12±15.82%respectively;F?:C were 99.65±13.30%,98.19±10.36%and 97.65±13.98%respectively,F?:C were 92.01 ± 10.46%,89.81±10.55%and 89.18±10.76%respectively,and the difference of all parameters among the three periods were not statistically significant(P>0.05 for all parameters).3.Compared to the day 0,the clotting factors activity of plasma samples diluted up to 5 times at the day 30 did not show significant differences(21.08±2.26%vs.20.49±3.06%,P=0.31 for F?:C;16.68±2.47%vs.16.56±3.17%,P=0.85for F?:C;21.91±2.83%vs.21.54±2.85%,P=0.42 for FIX:C;18.71±2.92%vs.18.10±2.42%,P=0.23 for F?:C).Compared to the day 0,the clotting factors activity of plasma samples diluted up to 10 times at the day 30 also did not show significant differences(11.14±1.53%vs.10.97±1.55%,P=0.61 for F?:C;8.71±1.22%vs.8.73±1.38%,P=0.95 for F?:C;11.57±1.61%vs.11.65±1.54%,P=0.65 for F?:C;9.08±1.63%vs.8.93±1.13%,P=0.53F X:C).4.The baseline and 30 days PIVKA-? were 22.87±5.85mAU/ml and 22.26±4.42mAU/ml respectively,and the difference was not statistically significant(P=0.19).Conclusion:1.Vitamin K2 supplementation does not affect vitamin K-dependent coagulation factors activity in healthy subjects.2.Vitamin K2 supplementation in healthy individuals does not decrease the level of uncarboxylated prothrombin(PIVKA-?),which indicates that healthy people have sufficient carboxylated prothrombin and the activity of thrombin will not be increased. |
PDF Full Text Request